Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 15/20 | 0.53 |
| ▸ | PDE4A | P27815 | 13/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 2/20 | 0.49 |
| ▸ | PDE1A | P54750 | 1/20 | 0.49 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.49 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19075751 | 0.90 | PDE4D (0.45) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL6799389 | 0.79 | HSD17B2 (0.58) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL3731756 | 0.76 | PDE4B (0.51) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL1976483 | 0.76 | EPHX2 (0.47) | EPHX2 | |
| Hydrochloric Acid SCHEMBL3731755 | 0.75 | RECQL (0.51) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL19075727 | 0.75 | LPAR1 (0.46) | — | |
| SCHEMBL17428526 | 0.75 | HTT (0.60) | — | |
| SCHEMBL7423009 | 0.74 | PDE4D (0.76) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL1807435 | 0.74 | LPAR1 (0.50) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL19075717 | 0.74 | PDE4A (0.74) | PDE4DPDE4APDE4BPDE4CEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | PDE4D 461/4885PDE4A 449/4885PDE4B 452/4885 |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | PDE4D 461/4885PDE4A 449/4885PDE4B 452/4885 |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | PDE4D 461/4885PDE4A 449/4885PDE4B 452/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | PDE4D 461/4885PDE4A 449/4885PDE4B 452/4885 |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | PDE4D 461/4885PDE4A 449/4885PDE4B 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.